MedTrace Logo

BES, EES, and ZES-R in Real World Practice

NCT01397175 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1960

Last updated 2019-07-09

No results posted yet for this study

Summary

The primary objective of this study is to compare the rate of device-oriented composite consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target lesion revascularization among the patients treated with EES, ZES-R, or BES at 24-month clinical follow-up post-index procedure. Trial end points are summarized in Table I. The hypothesis is that BES is equivalent to EES or BES is equivalent to ZES-R at the primary end point.

Conditions

Interventions

DEVICE

Biolimus-eluting stent

Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.

DEVICE

Everolimus-eluting stent

Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.

DEVICE

Zotarolimus-eluting stent

Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.

Sponsors & Collaborators

  • Gangwon Cardiovascular Health Research Institute

    collaborator OTHER

  • Yonsei University

    lead OTHER

Principal Investigators

  • Junghan Yoon, M.D., Ph.D. · Wonju Chrisitian Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-16
Primary Completion
2017-12-05
Completion
2019-01-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01397175 on ClinicalTrials.gov